A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa
Drug Delivery and Translational Research · 2026
DOI: 10.1007/s13346-026-02070-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2026. Verfasst von Matthew B Appell und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD, 21231, USA. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Antioxidants, Acetylcysteine, Photoreceptor Cells, Vertebrate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS, National Eye Institute.
Abstract (Originalsprache)
Retinitis pigmentosa (RP) is a chronic genetic condition that leads to progressive loss of photoreceptor cells and vision. While gene therapy is available for a small subset of patients with specific mutations, developing a therapeutic that broadly targets the cellular stresses that lead to cell death could address a major unmet need. One such option would be utilizing antioxidant therapies to neutralize reaction oxygen species (ROS) in the retina that underlie RP progression. Here, we describe an approach for delivering the antioxidants N-acetyl cysteine (NAC) or N-acetyl cysteine ethyl ester (NACET) with a gel-forming eye drop previously demonstrated to provide therapeutic drug delivery in the posterior segment in animals. We demonstrated therapeutic protection of photoreceptor structure and function in a chemically-induced rat model of RP (48% increase in photopic b-wave amplitude), as well as some limited protection in an aggressive genetic mouse model (rd10) of retinal degeneration (~ 31% increase in photopic b-wave amplitude) with once daily application. However, antioxidants have inherent stability issues when stored in solution, so we investigated the use of additional excipients to improve stability and retain potency. While a promising approach, future work to address product stability and efficacy in larger eyes is needed for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD, 21231, USA.
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
- Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD, 21231, USA.
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21218, USA.
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD, 21231, USA. lensign@jhmi.edu.
Förderung
- NEI NIH HHS
- National Eye Institute
Zitieren
APA
Appell, M. B., Kanan, Y., Malmberg, K., Appidi, T., Khan, M., Campochiaro, P. A., & Ensign, L. M. (2026). A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-026-02070-4
Vancouver
Appell MB, Kanan Y, Malmberg K, Appidi T, Khan M, Campochiaro PA, et al. A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa. Drug Delivery and Translational Research. 2026. doi:10.1007/s13346-026-02070-4
BibTeX
@article{Appell2026,
author = {Appell, Matthew B and Kanan, Yogita and Malmberg, Kiersten and Appidi, Tejaswini and Khan, Mahmood and Campochiaro, Peter A and Ensign, Laura M},
title = {A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa},
journal = {Drug Delivery and Translational Research},
year = {2026},
doi = {10.1007/s13346-026-02070-4}
}
EUVIMED